Kooperativer Bibliotheksverbund

UID:

ISBN: 9781524731663

Content: " A National Besteller Chilling...Reads like a West Coast version of All the President's Men. —,he New York Times Book Review The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley. "

Content: Rezension(1): "John Carreyrou is a two-time Pulitzer Prize-winning investigative reporter at the Wall Street Journal. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett &,Steele Silver Award for Investigative Business Journalism. Carreyrou lives in Brooklyn with his wife and three children." Rezension(2): "〈a href=http://www.publishersweekly.com target=blank〉〈img src=https://images.contentreserve.com/pw_logo.png alt=Publisher's Weekly border=0 /〉〈/a〉: Starred review from May 14, 2018 An apparent scientific breakthrough rests on a quicksand of deception in this riveting account of the rise and downfall of notorious biotech firm Theranos. Expanding on his award-winning investigative scoops, Pulitzer-winning Wall Street Journal reporter Carreyrou recounts how Elizabeth Holmes, a charismatic Stanford dropout, started Theranos with claims of a revolutionary blood-testing technology that needed just a few drops from a finger-prick rather than tubefulls drawn from veins with needles. Her start-up became the toast of Silicon Valley, with a $9 billion valuation and a board including former secretaries of state Henry Kissinger and George Shultz. The reality, he reports, was less stellar: the company’s flawed tests did not meet regulatory standards and gave dangerously inaccurate results, investors and journalists were snowed with fake demos, and Holmes and her second-in-command (and boyfriend), Sunny Balwani, dismissed employees’ concerns and drove many out with verbal abuse and computer surveillance. The author’s investigation is part of the story: as he pursues the truth, Theranos’s attorneys, led by Bush v. Gore lawyer David Boies, intimidate his sources with lawsuit threats. In the end it is Holmes who is targeted with a lawsuit by the Securities and Exchange Commission for “an elaborate, years-long fraud” and forced to relinquish voting control over the company and pay a six-figure penalty. Carreyrou blends lucid descriptions of Theranos’s technology and its failures with a vivid portrait of its toxic culture and its supporters’ delusional boosterism. The result is a bracing cautionary tale about visionary entrepreneurship gone very wrong. Agent: Eric Lupfer, Fletcher &,Company . " Rezension(3): "〈a href=http://www.kirkusreviews.com target=blank〉〈img src=https://images.contentreserve.com/kirkus_logo.png alt=Kirkus border=0 /〉〈/a〉: May 1, 2018 A deep investigative report on the sensationalistic downfall of multibillion-dollar Silicon Valley biotech startup Theranos.Basing his findings on hundreds of interviews with people inside and outside the company, two-time Pulitzer Prize-winning Wall Street Journal reporter Carreyrou rigorously examines the seamy details behind the demise of Theranos and its creator, Elizabeth Holmes. Founded in 2003, when Holmes was just 19, the company's claim to fame was its revolutionary blood-testing system, which touted the detection of everything from high cholesterol to hepatitis C to cancer using only one drop of blood. While raising $9 billion through a series of aggressive (and falsified) claims and dozens of private investors, the company's spiking net worth caught Carreyrou's attention a few years ago. His eye-opening reporting on the company's inaccurate, voided, or corrected test results, as well as the loss of major retail partnerships with Walgreens and Safeway, knocked Theranos off the tech radar and left it irreversibly devastated. The author glosses over Holmes' history as an unpopular high schooler and, later, Stanford dropout, focusing on her early vision of the specialized blood-reading equipment, the rapid evolution of Theranos, and the early skepticism about the device's efficacy and reliability. The well-integrated employee profiles and testimonies effectively support Carreyrou's damning narrative and discredit Holmes as a power-hungry, avaricious young leader who courted venture capitalists with specious claims. Former Theranos employees paint Holmes as an increasingly tyrannical leader who demanded allegiance and who swiftly terminated those who she felt fell short of ultimate loyalty. The author brilliantly captures the interpersonal melodrama, hidden agendas, gross misrepresentations, nepotism, and a host of delusions and lies that further fractured the company's reputation and halted its rise. More recently, the Securities and Exchange Commission slapped Theranos and Holmes with fraud charges, though she still touts her device as having improved accuracy and importance.Already slated for feature film treatment, Carreyrou's exposé is a vivid, cinematic portrayal of serpentine Silicon Valley corruption. COPYRIGHT(2018) Kirkus Reviews, ALL RIGHTS RESERVED. " Rezension(4): "〈a href=http://lj.libraryjournal.com/ target=blank〉〈img src=https://images.contentreserve.com/libraryjournal_logo.png alt=Library Journal border=0 /〉〈/a〉: June 15, 2018 Carreyrou's clearly written and accessible work can be compared to another outstanding business exposé, James B. Stewart's Den of Thieves --both are by Pulitzer Prize-winning Wall Street Journal reporters, both are based on deep investigative reporting, and both provide riveting accounts of business greed and fraud. In March 2018, Elizabeth Holmes and the health technology company Theranos settled SEC civil fraud charges by Holmes divesting control of the business and paying a large fine. Her former partner's case is pending. This work demonstrates how Holmes founded Theranos while in school at Stanford to provide a revolutionary blood-monitoring device using minimal blood. Holmes aspired to be like Steve Jobs, copying his dress and managerial style. She charmed and cajoled wealthy and powerful mentors who helped her raise millions. Inside the company, she and her partner terrorized highly skilled employees who were fired when they could not deliver quick results to match her promises. To stave off questions, the company believed it could fake-it-until-you-make-it, a Silicon Valley flaw, per Carreyrou. Using aggressive tactics and pit bull attorneys, Theranos squelched dissent and threatened the author. VERDICT Highly recommended for all collections. --Harry Charles, St. LouisCopyright 2018 Library Journal, LLC Used with permission. "

Language: English

URL: https://samples.overdrive.com/?crid=5e6a98c7-5d22-4478-9f5e-7531c563bdaa&.epub-sample.overdrive.com

URL: http://voebb.lib.overdrive.com/ContentDetails.htm?ID=5E6A98C7-5D22-4478-9F5E-7531C563BDAA

Author information: Carreyrou, John